ICOC President's Report June 2024



Logo Update

Koren Temple-Perry
Public Outreach & Communications
President's Report
June 27, 2024





Logo Refresh Updates



The Communications Team recommended a logo refresh as part of broader branding update.



Goals of logo refresh:

- 1. Improve readability and visibility in our name
- 2. Increase clarity of CIRM in many communities
- 3. Strengthen our current brand





CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE



Updated Logo Variations



- ✓ Legible
- ✓ Approachable
- ✓ Clean
- ✓ Human

The CIRM logo suite includes four primary variations of the logo: full-color (sometimes referred to as "four-color"), white, blue, and Spanish.





Full-color logo

All-white logo variation



All-blue logo variation

Full-color Spanish Logo

INSTITUTO DE MEDICINA

REGENERATIVA DE CALIFORNIA



New Branded Collateral



CIRM branded suite of 1-pagers, PPT templates, brochures, email signatures, branded letterhead, social media headers to align with updated design



CIRM's Mission

Accelerating world class science to deliver transformative regenerative medicine treatments in an equitable manner to a diverse California and world.

CIRM's Vision

Since CIRM's inception in 2004, the Agency has invested \$4.2 billion to fund regenerative medicine research, infrastructure, and education programs CIRM advances regenerative medicine in California through collaboration, innovation, and support for all stages of research, while also addressing manufacturing challenges and promoting inclusivity and diversity in the field.



CONTACT US

INFO@CIRM CA GOV

601 GATEWAY BLVD. SUITE 400

SOUTH SAN FRANCISCO, CA 94080

(510) 340-9101

CIRM.CA.GOV

Accelerating Regenerative **Medicine for** California and the World



As a world leader in regenerative medicine and stem cell research, the California Institute for Regenerative Medicine (CIRM) provides funding for innovative regenerative medicine, stem cell, and gene therapy research.



Innovation One Patient at a Time

Medicine (CIRM) accelerates the translation of groundbreaking discoveries into therapies, taking us one step closer to progress that can make a difference in people's lives.



CIRM.CA.GOV



rch at every level.

VERONICA MCDOUGALL

New Vision, New Hope

Veronica was diagnosed with retinitis pigmentosa (RP), a rare degenerative condition of the retina that would eventually leave her legally blind. She enrolled in a clinical trial at UC Irvine funded by CIRM and led by the biotech company jCyte. In the trial, a dedicated research team injected retinal progenitor cells into her left eye, leading to steady vision improvement. Although her vision deteriorated during her senior year of college, she joined a second CIRMfunded jCyte clinical trial, resulting in even stronger vision in her left eye. Veronica and her partner, Robert, now embrace parenthood with their son, Elliott.



HATAALII TIISYATONII ("HT") BEGAY

Four-Year-Old Medical Pioneer

Shortly after his birth in the Navajo nation, Hataalii Tiisyatonii ("HT") Begay was diagnosed with Artemis Severe Combined Immunodeficiency Disease (SCID). This meant he had no functioning immune system, leaving him at risk of deadly infections. HT was the first child to participate in a CIRM-funded UCSF trial where lead investigators collected his own blood stem cells, modified them with a healthy version of the defective gene, and then re-infuse the corrected cells back into his body to rebuild his immune system. Thanks to this CIRM-funded therapy. HT is an energetic and healthy little boy who is home and off his medications.



Potential to Suppress Seizures in a Single Dose

Annette's life transformed after joining a CIRM-funded trial for drug-resistant epilepsy with Neurona Therapeutics. In the trial, she received a single dose of a neuronal cell therapy derived from human stem cells, known as NRTX-1001. In the past, Annette endured frequent seizures, but thanks to this groundbreaking therapy, she has had a greater than 90% reduction in seizure frequency, allowing her to do the activities she loves. CIRM has supported Neurona's research from the initial discovery research stage to the ongoing first-in-human clinical trial, which was supported with an \$8 million grant

\$438 Million

Through education

programs, CIRM ie

helping train the

next generation of

medicine scientists

needed to advance

and technicians

regenerative

CIRM's infrastructure program builds real and virtual centers that provide the expertise, and information neede

11111

Infrastructure

\$578 Million

to advance CIRM's

*As of January 2024

rch, Translational Research, Clinical Research,

ential pillar that enables CIRM to advance its

CIRM CIRM.CA.GOV

601 GATEWAY BLVD, SUITE 400 SOUTH SAN FRANCISCO, CA 94080

Shared Resources Labs for Stem Cell-Based Modeling (SRL) Update


Uta Grieshammer, Ph.D.
Scientific Programs and Education
President's Report
June 27, 2024





cells (hESC)


Shared Resources Labs (SRLs) for Stem Cell-Based Modeling Timeline



cells (hiPSCs)




Shared Resources Labs – Network






Shared Resources Labs – 5 SRLs Launching





Shared Resources Labs – 11 Resubmissions




DISC-4 (ReMIND*) Update

Chan Lek Tan, Ph.D.
Scientific Programs and Education
President's Report
June 27, 2024



ReMIND Program – Update




Discussions during program concept development highlighted 3 main points:

- Lack of understanding of **disease mechanisms** as a major obstacle to therapeutic development
- Necessity of an integrative, multidisciplinary approach to tackle complex brain disorders
- Breakthroughs can be accelerated by knowledge and resource sharing



ReMIND Program – 2 Unique Awards

\$110M approved to tackle complex neuropsychiatric diseases



ReMIND-L (DISC4)

Collaborative projects

4 years

Up to \$10M / Award*

5 or more investigators

6 awards

\$88.2M total

ReMIND-X (DISC5)

RFA expected Q4 2024

*direct project cost maximum



ReMIND-L (DISC4) Applicants

- 26 Collaborative Applications across CA
- 16 of 26 applications were multi-institutional
- Applicants included 158 investigators from 19 institutions



Distribution of 26 primary applicant organizations

Multidisciplinary teams

Diverse research disciplines



Functional genomics, gene editing



2D and 3D stem-cell models, Scalable in-vitro phenotyping



Imaging, proteomic and metabolomics.

Al/ML approaches



Viral targeting, target identification, biomarker discovery



Clinical phenotyping, patient data and patient derived cell lines



ReMIND – Team contributions and next steps



Review **complete** (GWG)
Pending approval **August ARS**





Thank you!